Press Releases
Keyword Search
08.07.19
OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update
07.30.19
OpGen Announces Date of Second Quarter 2019 Financial Results Conference Call
06.27.19
OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy
06.13.19
OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection
05.14.19
OpGen Reports First Quarter 2019 Financial Results and Provides Business Update
05.14.19
OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
05.07.19
OpGen Announces Date of First Quarter 2019 Financial Results Conference Call
03.29.19
OpGen Announces Closing of Public Offering of Common Stock
03.28.19
OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal
03.26.19
OpGen Announces Pricing of a $5.4 Million Public Offering of Common Stock